Analyst Conference Summaries

Biotechnology Investor Aids

Incyte
INCY

conference date: October 31, 2017 @ 7:00 AM Pacific Time

Incyte Q3 Result Could Be An Upward Inflection Point [Seeking Alpha, 11/2/2017]

Pharmacyclics, BioMarin, And Incyte: A Quick Screen [Seeking Alpha, 3/26/2015]

2017
Feb. 14, 2017
May 4, 2017
 August 1, 2017
Oct. 31, 2017
2016
02/11/2016
05/09/2016
08/09/2016
11/01/2016

Incyte (INCY) is a commercial-stage biotechnology company specializing in targetted cancer therapies and immunotherapies.

Incyte web site

I bought a small, initial position in Incyte on November 1, 2016 after Q3 results came it. It is a long-term position based on the extensive pipeline. My intention is to accumulate more if the price is reasonable.

 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 INO
 INTC
 ISRG
 JUNO
 MACK
 MCHP
 MYL.
 NVDA
 PLX
 REGN
 SGEN
 XLNX
 XLRN
 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.

Copyright 2017 William P. Meyers